36 74

Cited 0 times in

Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck

DC FieldValueLanguage
dc.contributor.author고윤우-
dc.contributor.author김세헌-
dc.contributor.author김진아-
dc.contributor.author김한상-
dc.contributor.author김혜련-
dc.contributor.author백순명-
dc.contributor.author심효섭-
dc.contributor.author윤선옥-
dc.contributor.author조병철-
dc.contributor.author최은창-
dc.contributor.author홍민희-
dc.date.accessioned2021-01-19T07:46:15Z-
dc.date.available2021-01-19T07:46:15Z-
dc.date.issued2020-12-
dc.identifier.issn0007-0920-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/181323-
dc.description.abstractBackground: Recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) is a common cancer with high recurrence and mortality. Current treatments have low response rates (RRs). Methods: Fifty-three patients with R/M SCCHN received continuous oral buparlisib. In parallel, patient-derived xenografts (PDXs) were established in mice to evaluate resistance mechanisms and efficacy of buparlisib/cetuximab combination. Baseline and on-treatment tumour genomes and transcriptomes were sequenced. Based on the integrated clinical and PDX data, 11 patients with progression under buparlisib monotherapy were treated with a combination of buparlisib and cetuximab. Results: For buparlisib monotherapy, disease control rate (DCR) was 49%, RR was 3% and median progression-free survival (PFS) and overall survival (OS) were 63 and 143 days, respectively. For combination therapy, DCR was 91%, RR was 18% and median PFS and OS were 111 and 206 days, respectively. Four PDX models were originated from patients enrolled in the current clinical trial. While buparlisib alone did not inhibit tumour growth, combination therapy achieved tumour inhibition in three of seven PDXs. Genes associated with apoptosis and cell-cycle arrest were expressed at higher levels with combination treatment than with buparlisib or cetuximab alone. Conclusions: The buparlisib/cetuximab combination has significant promise as a treatment strategy for R/M SCCHN. Clinical trial registration: NCT01527877.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherNature Publishing Group on behalf of Cancer Research UK-
dc.relation.isPartOfBRITISH JOURNAL OF CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleMouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Otorhinolaryngology (이비인후과학교실)-
dc.contributor.googleauthorHye Ryun Kim-
dc.contributor.googleauthorHan Na Kang-
dc.contributor.googleauthorMi Ran Yun-
dc.contributor.googleauthorKwon Young Ju-
dc.contributor.googleauthorJae Woo Choi-
dc.contributor.googleauthorDong Min Jung-
dc.contributor.googleauthorKyoung Ho Pyo-
dc.contributor.googleauthorMin Hee Hong-
dc.contributor.googleauthorMyoung-Ju Ahn-
dc.contributor.googleauthorJong-Mu Sun-
dc.contributor.googleauthorHan Sang Kim-
dc.contributor.googleauthorJinna Kim-
dc.contributor.googleauthorJinseon Yoo-
dc.contributor.googleauthorKyu Ryung Kim-
dc.contributor.googleauthorYoon Woo Koh-
dc.contributor.googleauthorSe Heon Kim-
dc.contributor.googleauthorEun Chang Choi-
dc.contributor.googleauthorSun Ock Yoon-
dc.contributor.googleauthorHyo Sup Shim-
dc.contributor.googleauthorSoonmyung Paik-
dc.contributor.googleauthorTae-Min Kim-
dc.contributor.googleauthorByoung Chul Cho-
dc.identifier.doi10.1038/s41416-020-01074-2-
dc.contributor.localIdA00133-
dc.contributor.localIdA00605-
dc.contributor.localIdA00605-
dc.contributor.localIdA01022-
dc.contributor.localIdA01022-
dc.contributor.localIdA01098-
dc.contributor.localIdA01098-
dc.contributor.localIdA01166-
dc.contributor.localIdA01166-
dc.contributor.localIdA01823-
dc.contributor.localIdA01823-
dc.contributor.localIdA02219-
dc.contributor.localIdA02219-
dc.contributor.localIdA02566-
dc.contributor.localIdA02566-
dc.contributor.localIdA03822-
dc.contributor.localIdA03822-
dc.contributor.localIdA04161-
dc.contributor.localIdA04161-
dc.contributor.localIdA04393-
dc.contributor.localIdA04393-
dc.relation.journalcodeJ00406-
dc.identifier.eissn1532-1827-
dc.identifier.pmid32963347-
dc.contributor.alternativeNameKoh, Yoon Woo-
dc.contributor.affiliatedAuthor고윤우-
dc.contributor.affiliatedAuthor김세헌-
dc.contributor.affiliatedAuthor김세헌-
dc.contributor.affiliatedAuthor김진아-
dc.contributor.affiliatedAuthor김진아-
dc.contributor.affiliatedAuthor김한상-
dc.contributor.affiliatedAuthor김한상-
dc.contributor.affiliatedAuthor김혜련-
dc.contributor.affiliatedAuthor김혜련-
dc.contributor.affiliatedAuthor백순명-
dc.contributor.affiliatedAuthor백순명-
dc.contributor.affiliatedAuthor심효섭-
dc.contributor.affiliatedAuthor심효섭-
dc.contributor.affiliatedAuthor윤선옥-
dc.contributor.affiliatedAuthor윤선옥-
dc.contributor.affiliatedAuthor조병철-
dc.contributor.affiliatedAuthor조병철-
dc.contributor.affiliatedAuthor최은창-
dc.contributor.affiliatedAuthor최은창-
dc.contributor.affiliatedAuthor홍민희-
dc.contributor.affiliatedAuthor홍민희-
dc.citation.volume123-
dc.citation.number12-
dc.citation.startPage1720-
dc.citation.endPage1729-
dc.identifier.bibliographicCitationBRITISH JOURNAL OF CANCER, Vol.123(12) : 1720-1729, 2020-12-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Otorhinolaryngology (이비인후과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.